Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Anti-Cancer Drugs

• Publication date

  2009-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/CAD.0b013e3283264719PMID 19182679
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel

  2008cited by this paper
• Efficacy of neoadjuvant bevacizumab (Av), capecitabine (X), and docetaxel (T) for invasive breast cancer (BC): Phase II result

  2008cited by this paper
• Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.

  2007cited by this paper
• Inflammatory breast cancer (IBC) and patterns of recurrence

  2007cited by this paper
• Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

  2007cited by this paper
• Inflammatory Breast Cancer as a Model Disease to Study Tumor Angiogenesis: Results of a Phase IB Trial of Combination SU5416 and Doxorubicin

  2007cited by this paper
• CANCER PATIENTS

  2006cited by this paper
• The multifaceted circulating endothelial cell in cancer: towards marker and target identification

  2006cited by this paper
• Phase II Trial of Bevacizumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patients

  2006cited by this paper
• A phase II study of primary dose-dense sequential doxorubicin plus cyclophosphamide and docetaxel in cT4 breast cancer.

  2006cited by this paper
• Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer.

  2006cited by this paper
• Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

  2005cited by this paper
• Association between HER-2/neu and Vascular Endothelial Growth Factor Expression Predicts Clinical Outcome in Primary Breast Cancer Patients

  2004cited by this paper
• Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy.

  2004cited by this paper
• Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors

  2004cited by this paper
• Assessing Tumor Angiogenesis

  2004cited by this paper
• International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations.

  2003cited by this paper
• Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel.

  2002cited by this paper
• Revision of the American Joint Committee on Cancer staging system for breast cancer.

  2002cited by this paper
• Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth

  2001cited by this paper
• Resting and activated endothelial cells are increased in the peripheral blood of cancer patients.

  2001cited by this paper
• Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.

  2001cited by this paper
• Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma.

  2001cited by this paper
• In vitro differentiation of endothelial cells from AC133-positive progenitor cells

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• [New guidelines to evaluate the response to treatment in solid tumors].

  2000cited by this paper
• In vitro differentiation of endothelial cells from AC133-positive progenitor cells.

  1999cited by this paper
• Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.

  1999cited by this paper
• Isolation of Putative Progenitor Endothelial Cells for Angiogenesis

  1997cited by this paper
• The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques.

  1996cited by this paper
• Angiogenesis in cancer, vascular, rheumatoid and other disease

  1995cited by this paper
• Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.

  1995cited by this paper

• Impact of wait time from neoadjuvant chemotherapy to surgery in breast cancer: Does time to surgery affect patient outcomes?

  2020cites this paper
• Weekly paclitaxel and cisplatin as neoadjuvant chemotherapy with locally advanced breast cancer: a prospective, single arm, phase II study

  2017cites this paper
• Impaired wound healing and expansion of a large ulcer after bevacizumab with paclitaxel for skin metastases from breast cancer: report of a case

  2014cites this paper
• Antiangiogenic therapy: Patient selection and clinical outcomes

  2014cites this paper
• A systematic review of bevacizumab efficacy in breast cancer.

  2014cites this paper
• Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.

  2013cites this paper
• Systemische Induktionschemotherapie bei Brustkrebs

  2013cites this paper
• Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response

  2013influential citation
• Bevacizumab and breast cancer: what does the future hold?

  2012cites this paper
• Promising therapeutic options in triple-negative breast cancer.

  2012cites this paper
• Advances in the Management of Triple Negative Breast Cancer

  2011cites this paper
• Combined therapies and future directions

  2011cites this paper
• Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer

  2010cites this paper
• Antiangiogenic therapy for breast cancer

  2010cites this paper
• Antiangiogenic therapies in early-stage breast cancer.

  2010cites this paper
• Impaired Wound Healing and Bilateral Mastectomy Flap Necrosis in a Patient With Locally Advanced Breast Cancer After Neoadjuvant Paclitaxel With Bevacizumab

  2010cites this paper
• Systemic therapy of inflammatory breast cancer from high‐dose chemotherapy to targeted therapies

  2010cites this paper
• IEO Breast Cancer Treatment Recommendations

  2010cites this paper
• Bevacizumab and breast cancer: current therapeutic progress and future perspectives

  2009cites this paper
• Pharmacotherapy of triple-negative breast cancer

  2009cites this paper